Harrison.ai vs Gleamer (2026)
Two European and Australian radiograph companies pointed at different films. Gleamer is musculoskeletal first, detecting fractures, effusions, dislocations and bone lesions, with a clearance covering both adult and pediatric use, backed by a fully crossed multiple reader, multiple case study. Harrison.ai, formerly Annalise, is chest first, with comprehensive findings coverage, regulatory footprints across several markets and greater deployment maturity. A department choosing between them is really choosing which queue to attack: the overnight trauma films or the chest backlog. Neither publishes a security attestation on its main site, and Gleamer's multi party distribution makes the stewardship question harder to answer than it looks.
- Comprehensive chest radiograph coverage across a large findings set with regulatory footprints in multiple markets and more than a third of NHS England chest X-rays.
- Deployment maturity is greater, which matters for a modality where the failure is a subtle finding missed at scale rather than a dramatic error.
- For a health system standardizing chest radiograph AI across sites, the more widely deployed platform carries fewer unknowns.
- Its fracture detection clearance covers both adult and pediatric use.
- The clearance study design is a fully crossed multiple reader multiple case study rather than a retrospective sample.
- Distribution breadth substitutes for integration engineering, available directly and through several imaging platform partners.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Harrison.ai and Gleamer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Harrison.ai | Gleamer |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2019 | 2017 |
| Headquarters | Sydney, Australia | Saint-Mandé, France |
| Website | harrison.ai | gleamer.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Harrison.ai, headquartered in Sydney, sells radiology AI that until 2025 was sold under the Annalise.ai name. Harrison.ai combined with Annalise.ai in February 2025 and renamed the Annalise products in October 2025, and the annalise.ai domain now forwards to harrison.ai.
Source: AI Health Index, August 2026
Gleamer SAS is a radiology AI company based in Saint-Mandé, on the edge of Paris, and since 2 March 2026 part of DeepHealth, the digital health subsidiary of the US imaging services operator RadNet, Inc. RadNet announced the all cash acquisition at up to 230 million euros, about 215 million at closing plus a 15 million contingent milestone. Gleamer's site and products keep the Gleamer name.
Source: AI Health Index, August 2026
Questions buyers ask
How do Harrison.ai and Gleamer work with the EHR?
For Harrison.ai, the 510(k) summary for K222268 describes the software receiving DICOM chest X-ray studies from image and order management systems such as a PACS or RIS, running in parallel with the standard workflow, and returning a case level result to the PACS or RIS for worklist prioritization.
Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, since March 2026, and nothing published says whether the products now run inside DeepHealth's platform or remain available on other vendors' archives. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Harrison.ai and Gleamer priced and sold?
In Harrison.ai's case, the products are sold to healthcare organizations (public hospitals, private hospitals and private radiology providers) by contacting the company, and the site states they are not available for purchase by the general public.
For Gleamer, the packaging and the owner are public. The products are sold as modules of the Gleamer Copilot suite, and since March 2026 Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, so contracting may run through DeepHealth. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Harrison.ai and Gleamer handle patient data?
With Harrison.ai, the company's privacy notice (last updated 20 November 2025), which covers its products and services as well as its websites, states that it does not use any content uploaded into its services, including demos, product trials and evaluations, for model training.
When Gleamer receives patient data from a customer, including imaging examinations and reports, it acts as the customer's processor and works on pseudonymized data, and where the customer authorizes it, Gleamer may anonymize pseudonymized patient data and use the anonymized result for its own purposes, including training and developing its products. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Harrison.ai and Gleamer cover?
For Harrison.ai, the company sells chest X-ray (up to 124 findings), non contrast head CT (up to 130 findings) and chest CT (up to 167 radiological features) to public hospitals, private hospitals and private radiology providers, with solution pages for emergency and acute care and for oncology management, and states clearance for clinical use in more than 40 countries. The US triage clearances carry defined, validated populations.
With Gleamer, the suite now claims far wider coverage, described by the company as covering all imaging modalities, with products for chest X-ray, chest CT, bone CT, breast imaging, brain MRI and lumbar spine MRI. Validation for those is not summarized on the home page, and ChestView and BoneMetrics have their own FDA summaries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These read different films for different purposes and should be compared per body region rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface. Neither vendor publishes a security attestation on its main site, though Harrison.ai, formerly Annalise, runs a trust center. Gleamer's multi party distribution model makes the data stewardship question harder to answer, since it publishes no business associate terms and the responsible party varies by delivery path.